Danaparoid (Orgaran)

Topic Completed: 1 June 2012

Revised: 4 January 2019, last major update June 2012

Copyright: (c) 2002-2016,, Inc.

PubMed Search: Danaparoid (Orgaran)

Page views in 2019: 39
Page views in 2020 to date: 31
Cite this page: Parsons J. Danaparoid (Orgaran). website. Accessed August 14th, 2020.
Definition / general
  • Approved to prevent deep venous thromboses
  • Also an alternative to heparin for patients with heparin induced thrombocytopenia (Crit Care 2007;11:R102)
  • Use is decreasing due to newer anticoagulants
  • Composed of low molecular weight glycosaminoglycans (mixture of heparan sulfate, dermatan sulfate and chondroitin sulfate) that primarily inhibit factor Xa, factor IIa to a much lesser extent
Clinical features
  • Similar to low molecular weight heparin in having a more predictable anticoagulant effect, with less need for laboratory monitoring
  • Monitor, if desired, by measuring inhibitor of factor Xa using standard curve; draw 6 hours after subcutaneous injection; PT and PTT are unaffected
  • Therapeutic levels to treat DVT are 0.5 - 0.8 anti-factor Xa units/ml, lower for DVT prophylaxis
  • Long half-life, is prolonged with renal failure
  • No reversal agent is known, but incomplete reversal is shown with protamine sulfate
  • Not marketed in the US since 2004, still available in some countries.
Back to top